The Food and Drug Administration has accepted a Biologics License Application for Tevimbra with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
After I was diagnosed with colon cancer, I learned to take care of myself more and be more outspoken than ever before.
A patient in a phase 2 trial has received the first dose of a novel combination of botensilimab and balstilimab plus agenT-979, an allogeneic cell therapy.
Spending a fourth of my life as a cancer survivor, I’ve learned a few lessons along the way.
I wondered how much I could contribute to cholangiocarcinoma awareness, but determined that if I help just one person, then that's a success.
The Food and Drug Administration has approved Onivyde with oxaliplatin, fluorouracil and leucovorin, for the first-line treatment of patients with metastatic pancreatic adenocarcinoma, the agency has announced.
Country singer Toby Keith died Monday after receiving a stomach cancer diagnosis in 2022.
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.
Slower infusion rates of antiemetic drugs may help manage nausea and vomiting in patients with gastric or gastroesophageal junction cancers.
A vaccine for pancreatic and colorectal cancers is showing promise, but potential availability of the drug is likely several years away, an expert said.
Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.
My wife's simple sentence to me ended up saving my life from colorectal cancer.
Dr. Dustin Deming, a gastrointestinal oncologist, began his own cancer journey more than a decade ago when he received a diagnosis of rectal cancer.
Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.
Older adults with gastric cancer tended to have better outcomes when they walked 2,500 steps per day or more.
Findings presented at the 2024 Gastrointestinal Cancers Symposium support Fruzaqla’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.
Circulating tumor DNA-based minimal residual disease lent insight into which patients with stage 2/3 colorectal cancer may be at higher risk for recurrence and which could benefit from postsurgical chemotherapy.
Patients with resectable mismatch repair-proficient and -deficient colorectal cancer had robust responses to neoadjuvant botensilimab/balstilimab.
In patients with esophageal squamous cell carcinoma, the combination of Tecentriq, tiragolumab and chemotherapy improved survival outcomes, research found.
In patients with TRK fusion GI cancers, Vitrakvi continued to show improvements regarding responses to treatment, survival and safety, research found.
The use of FOLFOXIRI for metastatic colorectal cancer was lower than one what expert was expecting.
The use of the chemotherapy regimen FOLFOXIRI plus Avastin has increased from 2013 to 2022 in patients with metastatic colorectal cancer, particularly in patients aged 50 years and younger.
Certain patients with metastatic colorectal cancer were more likely to have long-term remission to Stivarga treatment, recent research showed.
Imfinzi plus chemotherapy, when given before surgery, improved pathologic complete response rates, regardless of region, in certain patients with gastric or gastroesophageal junction cancers.
Treatment with Opdivo and chemotherapy improved survival in patients with gastrointestinal cancers, compared with chemotherapy alone, according to a phase 3 trial.
